Biotech company Alvotech S.A. (NASDAQ:ALVO) announced on Tuesday an agreement with German pharmaceutical company STADA Arzneimittel AG (FWB:SAZ) to form a broader biosimilar partnership.
Under the new agreement STADA gets marketing rights for Alvotech's AVT03, a clinical-stage biosimilar candidate referencing Prolia/Xgeva (denosumab), in Europe and parts of Central Asia and the Middle East. This builds on their existing alliance for biosimilars.
Alvotech will develop and manufacture AVT03, targeting osteoporosis and cancer-related bone loss. Upon approval, STADA will commercialise it in specified territories.
The agreement also expands STADA's commercial rights to existing Alvotech biosimilars in Central Asia, while Alvotech will regain commercial rights from STADA to AVT06, a proposed biosimilar to Eylea (aflibercept).
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen